SAB-185

DB16491InvestigationalProtein Based Therapies

SAB-185: Overview.

Mechanism: SAB-185, a fully-human polyclonal antibody is being investigated against COVID-19. Preliminary studies demonstrate the potential for this antibody to be more potent in neutralizing live SARS-CoV-2 than convalescent plasma.
Curator reviewed
Also known as: ANTI-SARS-COV-2 HUMAN IMMUNOGLOBULIN INTRAVENOUS (TC BOVINE-DERIVED), · Anti-SARS-CoV-2 Polyclonal Antibodies SAB-185 · HUMAN IGG POLYCLONAL ANTIBODY DERIVED FROM PLASMA OF TRANSCHROMOSOMAL BOVINE TARGETED TO THE SPIKE PROTEIN OF SARS COV-2
Code names: SAB-185

Resolves to

Compound

Targets

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with SAB-185, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.